In closing IMO PSID is headed to levels we could NOT have imagined it EVER going to. I will be HOLDING on to 75% of my shares that i have spread over 3 different accounts. The other 25% i wil trade accordingly.
Looks to me like a NO-BRAINERRRRRRRR!!!! DHS needs PSID as well as the rest of the world! M-BAND IMO is going to be a HUUUUUUGE GAME changer for PSID. Consider yourself blessed to have discovered and remained PATIENT with your investment in PSID! MBD
======================================================= http://investorshub.advfn.com/boards/read_msg.aspx?message_id=73459048 PositiveID Corporation Awarded U.S. Patent No. 8,133,451 for First-of-Its-Kind Detection System for Molecular Biological Diagnostics Company's New Dragonfly System Detects Multiple Strains of Influenza, E.coli, MRSA, HPV and Other Illnesses Within 30 Minutes, Significantly Faster Than Existing Systems GlobeNewswirePress Release: PositiveID Corporation – 17 minutes ago
DELRAY BEACH, Fla., March 20, 2012 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID") (OTCBB:PSID.OB - News), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense industry, announced today that it was awarded U.S. Patent No. 8,133,451 for its Dragonfly(TM) Rapid MDx Cartridge-based diagnostic system, which provides the ability to deliver molecular diagnostic results from a sample in less than 30 minutes. Dragonfly enables accurate diagnostics leading to the potential treatment scenarios at the point of care that are not possible with existing systems.
Dragonfly has been proven effective for a broad range of biological detection including radiation-induced cell damage within the human body, strains of influenza and other common pathogens and diseases such as E. coli, methicillin-resistant staphylococcus aureus (MRSA) and human papilloma virus (HPV). Dragonfly offers the precision of molecular diagnostics in an easy-to-use cartridge format that minimizes the possibility of human error. Typical current molecular diagnostic testing can take hours or even days, requires highly trained personnel and includes multiple handling steps.
William J. Caragol, Chairman and CEO of PositiveID, stated, "With Dragonfly, we have the ability to revolutionize the way healthcare is administered by enabling accurate diagnosis within minutes at the point of care, and before the patient leaves the physician's office. This allows healthcare professionals to prescribe the appropriate treatments immediately, helping to minimize the overuse of antibiotics, and enables rapid treatment and potential monitoring and quarantine measures for serious outbreaks such as certain forms of influenza."
12B007......Received this from one of my accounts!
Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting
2012 POSITIVEID CORPORATION Annual Meeting of Stockholders
MEETING DATE: May 31, 2012 For Holders as of: April 9, 2012 CUSIP NUMBER: 73740J100
=========================================================== another one in diabetes research as froi http://investorshub.advfn.com/boards/read_msg.aspx?message_id=72044821 PositiveID Achieves Positive Preliminary Results From Diabetes Research Institute Study at the University of Miami PrintAlert Positiveid Corporati (OTCBB:PSID) Intraday Stock Chart Today : Monday 13 February 2012
PositiveID Corporation ("PositiveID") (OTCBB:PSID), a developer of medical technologies for diabetes management, announced today positive preliminary results from its biotransport research study with the Diabetes Research Institute ("DRI") at the University of Miami relating to PositiveID's GlucoChip™. GlucoChip is a glucose-sensing implantable microchip, currently under development with partner RECEPTORS LLC, for individuals with diabetes. Preliminary results demonstrate that the membrane materials to be used with GlucoChip allow for successful movement of glucose from body fluids.
PositiveID's first animal studies were designed to test the membrane materials that will be the interface between the glucose sensing device and the in vivo environment by evaluating the ability of glucose to pass through the membrane to the sensing device (glucose transport).
Medical Technology Stock Alert; PositiveID Corporation (OTCBB:PSID ... - InvestorIdeas.com
May 14, 2012 (Investorideas.com newswire) - PositiveID Corporation's (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's ... PositiveID Corporation Collaborates With the University of Nevada to Complete ...GlobeNewsWire (press release)
JAKARTA, Indonesia (AP) - Indonesia became the first country to suspend imports of U.S. beef Thursday following the discovery this week of an American dairy cow infected with mad cow disease.
Reaction elsewhere in Asia, however, was muted with no immediate signs some of the biggest consumers, South Korea and Japan, would follow suit. Both countries are close U.S. allies and their governments are balancing that key relationship against the protectionist demands of their domestic meat industries.
Market Data 
Markets 
AI
